CASI Pharmaceuticals (CASIF) Non-Current Debt (2021 - 2024)
CASI Pharmaceuticals' (CASIF) quarterly Non-Current Debt came in at $18.5 billion in Q2 2024, up 99248.97% on a QoQ basis from $18.6 million in Q1 2024.
CASI Pharmaceuticals (CASIF) Non-Current Debt (2021 - 2024) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Non-Current Debt data on file, last reported at $18.5 billion in Q2 2024.
- Quarterly Non-Current Debt changed N/A year-over-year to $18.5 billion in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $18.5 billion (changed N/A YoY) and the FY2023 annual result came in at $18.9 billion, up 159742.65% from the prior year.
- Non-Current Debt advanced to $18.5 billion in Q2 2024, from $18.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $18.9 billion in Q4 2023 to a low of $11.8 million in Q4 2022.
- A 4-year average of $7.5 billion and a median of $18.6 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt retreated 10.58% — and 2023, when it soared 159742.65%.
- Tracing CASIF's Non-Current Debt over 4 years: stood at $13.2 million in 2021, then retreated by 10.58% to $11.8 million in 2022, then soared by 159742.65% to $18.9 billion in 2023, then declined by 2.28% to $18.5 billion in 2024.
- The last three Non-Current Debt figures came in at $18.5 billion (Q2 2024), $18.6 million (Q1 2024), and $18.9 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 18.47 Bn |
| Mar 31, 2024 | 18.59 Mn |
| Dec 31, 2023 | 18.90 Bn |
| Dec 31, 2022 | 11.82 Mn |
| Dec 31, 2021 | 13.22 Mn |